Lymphocytotoxicity analysis
| Target cells . | Patients at onset of GVHD (N = 15) . | Patients without GVHD (N = 21) . | Controls N = 6 . |
|---|---|---|---|
| PHA-blasts | 12.9 ± 4.7* | 4.3 ± 0.9 | 1.5 ± 0.8 |
| T47D | 24.0 ± 5.0* | 12.6 ± 1.7 | 4.8 ± 1.2 |
| K562 | 53.0 ± 4.41-160 | 42.4 ± 2.4 | 50.1 ± 6.7 |
| Target cells . | Patients at onset of GVHD (N = 15) . | Patients without GVHD (N = 21) . | Controls N = 6 . |
|---|---|---|---|
| PHA-blasts | 12.9 ± 4.7* | 4.3 ± 0.9 | 1.5 ± 0.8 |
| T47D | 24.0 ± 5.0* | 12.6 ± 1.7 | 4.8 ± 1.2 |
| K562 | 53.0 ± 4.41-160 | 42.4 ± 2.4 | 50.1 ± 6.7 |
Maximum autocytolytic, anti-T47D, and natural killer cell activity observed during the interval (day 12 through day 33) for patients who developed autologous graft-versus-host disease (GVHD) confirmed by skin biopsy. Data for onset of GVHD represent the lytic activity when the patients developed clinical evidence of autologous GVHD. The results from patients without clinical manifestations of autologous GVHD and from 6 control autologous stem cell transplantation (SCT) patients (non-CsA treated) are presented for comparison. Lysis of the target cells was measured using a standard 51Cr release assay at a 100:1 effector-to-target ratio. Data expressed as mean ± SE.
P < .01,
P< .05 patients at onset of GVHD versus patients without GVHD group. PHA blasts indicates phytohemagglutinin-stimulated autologous lymphoblasts.